Aaron specialises in understanding and designing vaccines for pathogenic retroviruses.
In his PhD, Aaron is investigating the retrovirus Human T-lymphotropic Virus Type 1 (HTLV-1). He is using the second-generation molecular clamp technology to undertake preclinical and clinical development of a prefusion-stabilised vaccine against HTLV-1. Aaron completed his undergraduate degrees (BBiomedSc/BSc(Microbiology)) at UQ (2022) before receiving first class honours (2023) investigating the immunosuppressive function of the koala retrovirus (KoRV).